San Francisco, California, July 06, 2017: A market intelligence report by TMR Research, titled “Dermatophytosis Treatment Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017–2025,” offers a detailed evaluation of the trends and opportunities in the market. The report serves with a 360-degree view of the global dermatophytosis treatment market by providing insights into all important aspects, including diagnosis type, drug type, regional segmentation, and vendor landscape.
The widening pool of patients with weak immune systems is one of the primary factors augmenting the need for dermatophytosis treatment. The rapidly growing global population of geriatrics is also stoking the growth of the market, since immune system weakens with aging. Moreover, changing lifestyles play a pivotal role in the development of the dermatophytosis treatment market. People are shifting to sedentary routines, which include minimum physical activities, thereby hampering their immune systems. The increasing incidence of hospital-acquired diseases are resulting in higher rate of dermatophytosis, thereby providing a fillip to the market.
On the other hand, the lack of awareness about dermatophytosis results in a large section of patient pool remaining undiagnosed and untreated. This, in turn, limits the market from realizing its utmost potential. Additionally, reluctance on patients’ part in receiving dermatophytosis treatment is impeding the upward rise of the global market.
Geographically, North America and Europe will account for a large cumulative share in the global arena. The growth of these regions can be attributed to favorable reimbursement framework, the presence of advanced healthcare infrastructure, and rising healthcare spending. The increasing awareness among the populace regarding the merits of early diagnosis and treatment of dermatophytosis is also one of the primary factors contributing to the growth of the regions.
Asia Pacific offers immense growth opportunities to the global dermatophytosis treatment market. Developing healthcare infrastructure owing to the increasing efforts by governments is providing a significant push to the market in the region. China and India are poised to be sights of high growth rates during the forecast period, due to the rising awareness regarding dermatophytosis treatment among the populace. In Latin America, Argentina and Brazil will be the primary revenue contributors to the market.
The majority of key players in the global dermatophytosis treatment market are entering into collaborations with research institutes and universities for conducting clinical trials to develop effective treatment methods. Some of the prominent participants in the market are Novartis AG, Sun Pharmaceutical Industries Limited, Quinnova Pharmaceuticals Inc., NB Therapeutics Inc., Tinea Pharmaceuticals, Valeant Pharmaceuticals International Inc., AmDerma Pharmaceuticals LLC, Perrigo Company plc., and Merz Pharma GmbH & Co. KgaA.